Rani Therapeutics Holdings (RANI) EPS (Basic) (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted EPS (Basic) of -$0.04 for Q2 2026, down 1.04% on a QoQ basis from -$0.04 in Q1 2026, and up 85.35% year-over-year from -$0.02 in Q2 2025.
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) EPS (Basic) (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings has reported EPS (Basic) for 7 years, with the latest figure at -$0.04 in Q2 2026.
- On a quarterly basis, EPS (Basic) rose 85.35% year-over-year to -$0.04 in Q2 2026; TTM through Jun 2026 was -$0.18, a 87.76% increase from a year earlier, with the FY2025 full-year figure at -$0.61, up 69.28% from the prior year.
- EPS (Basic) was -$0.04 for Q2 2026 at Rani Therapeutics Holdings, down from -$0.04 in the prior quarter.
- The five-year high for EPS (Basic) was -$0.04 in Q1 2026, with the low at -$0.74 in Q2 2023.
- Average EPS (Basic) over 5 years is -$0.47, with a median of -$0.55 recorded in 2023.
- The sharpest annual moves came in 2022 and 2026: EPS (Basic) tumbled 460.12% in 2022, then surged 88.31% in 2026.
- Over 5 years, EPS (Basic) stood at -$0.73 in 2022, then gained by 24.45% to -$0.55 in 2023, then fell by 0.19% to -$0.55 in 2024, then soared by 76.73% to -$0.13 in 2025, then jumped by 64.98% to -$0.04 in 2026.
- The last three EPS (Basic) figures came in at -$0.04 (Q2 2026), -$0.04 (Q1 2026), and -$0.13 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | -0.40 |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - | -0.04 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.04 |
| Mar 31, 2026 | -0.04 |
| Dec 31, 2025 | -0.13 |
| Sep 30, 2025 | -0.17 |
| Jun 30, 2025 | -0.31 |
| Mar 31, 2025 | -0.38 |
| Dec 31, 2024 | -0.55 |
| Sep 30, 2024 | -0.44 |
| Jun 30, 2024 | -0.51 |
| Mar 31, 2024 | -0.57 |
| Dec 31, 2023 | -0.55 |
| Sep 30, 2023 | -0.72 |
| Jun 30, 2023 | -0.74 |
| Mar 31, 2023 | -0.67 |
| Dec 31, 2022 | -0.73 |
| Sep 30, 2022 | -0.66 |
| Jun 30, 2022 | -0.66 |
| Mar 31, 2022 | -0.65 |
| Dec 31, 2021 | -0.68 |
| Sep 30, 2021 | -1.48 |